Health Care Equipment & Services

Insider CFO buy‑options at Axe Compute signal exec confidence, yet AI‑oncology stock remains volatile; investors weigh tech promise against sharp price decline and negative P/E.

Guardant Health insider trades signal steady confidence while its liquid‑biopsy tests, backed by FDA clearance and solid clinical data, advance precision oncology—yet rising debt and integration hurdles call for careful investment and clinical appra…

Owlet CFO’s recent insider sale hints at cash‑flow shifts amid expansion plans, sparking investor focus on future funding and growth prospects.

Insider sales at PACS Group Inc. reveal routine cash‑flow management, not distress, while its robust pipeline—PG‑101, PG‑202, PG‑303—shows strong Phase II data and regulatory momentum for breakthrough cancer and rare‑disease therapies.

Schrodinger insider trades reveal CEO Farid Ramy buying low, selling high, boosting confidence in its AI drug‑discovery platform and signaling a strategic shift toward long‑term growth.

ENvue Medical’s EMG‑guided feeding‑tube, cleared by the FDA, offers safer, faster tube placement with a high‑margin consumable model—insider buys signal strong investor confidence and growing regulatory momentum.

Steve Cashman’s April 16 insider sale shows liquidity, not loss of confidence—insider moves, market impact, and what it means for investors.

Cardinal Health insider buys 381 shares before earnings, signaling confidence in future growth and robust sales of newly approved oncology drugs, with ongoing safety and regulatory updates.

HeartBeam’s IPO insider buying shows confidence in AI‑powered ECG tech, offering upside if FDA milestones hit despite a weak market outlook.

Insightful insider sales at Clover Health Investments reveal routine tax‑cover moves, new fertility plans, and evolving value‑based strategies—key data for investors.